In Brief: NDAC
This article was originally published in The Tan Sheet
Executive Summary
NDAC: Meeting of FDA's Nonprescription Drugs Advisory Committee tentatively scheduled for March 11-13 has been canceled; it is the fourth in a string of recent cancellations, following Glaxo Wellcome's withdrawal from the September review of the Rx-to-OTC switch of Beconase and the cancellation of tentatively scheduled December and January meetings due to lack of agenda items ("The Tan Sheet" Dec. 15, 1997, p. 1). Future NDAC discussions may focus on FDA's development of a monograph for sunscreen products, mandated by the FDA Modernization Act to be completed within 18 months of the law's Feb. 19 effective date. NDAC's Dental Plaque Subcommittee will continue its work on development of a plaque/gingivitis monograph at meetings scheduled for May 27-28, Oct. 7-8 and Dec. 2-3...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning